Sino-Argi Leading Biosciences (603970) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Sino-Argi Leading Biosciences ¥8.32, price ¥12.17, upside -31.6%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sino-Argi Leading Biosciences for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥9.63 – ¥25.13 · fair‑value band ¥5.20 – ¥13.17 · the ¥12.17 price screens above the ¥8.32 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Sino-Argi Leading Biosciences in your weekly email
Every Wednesday you see whether Sino-Argi Leading Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products.
Show more
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection technology services; and crop health solutions, including technical guidance, application demonstration, and processing and packaging of plant protection products. In addition, the company offers insecticides, fungicides, and herbicides products. The company was founded in 2009 and is headquartered in Beijing, China. Sino-Agri Leading Biosciences Co.,Ltd is a subsidiary of China National Agricultural Means of Production Group Corporation.
Stock analysis
Sino-Argi Leading Biosciences (603970) currently trades at ¥12.17, while our model-based Fair Value estimate is ¥8.32, implying the stock looks roughly 46.3% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥13.91 per share, and 5 of the 17 models we run sit above the ¥12.17 price.
Bear case: the Asset-Based group reads lowest at ¥3.93, and 12 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥5.20 (bear) to ¥13.17 (bull), the price of ¥12.17 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sino-Argi Leading Biosciences reported revenue of 11.2B CNY in FY2025 versus 8.8B CNY in FY2021, a compound +6.2%/yr. Reported net income was 173M CNY in FY2025, compounding +0.3%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $488M) · P/E ratio 18.7 · P/S ratio 0.29 · EPS (TTM) ¥0.6500 · Dividend yield 2.6% · Net margin 1.5% · Return on equity 10.6% · Return on assets (EBIT) 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 10% fair-value upside, at −32%, 603970 screens richer than that median.
Fair Value models
Bear ¥5.20Fair Value ¥8.32Bull ¥13.17
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2423 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.4%
Dividend (yield on the price)2.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5% vs 5%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Compare Sino-Argi Leading Biosciences with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 180 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−32% · Below median
Profitability
Return on equity (TTM)11% · Above median
Return on assets3% · Below median
Net margin (TTM)2% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth5% · Below median
Dividend yield (TTM)2.6% · Above median
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
P/E (TTM)18.7× · Pricier than median
P/B2.08× · Pricier than median
P/S (TTM)0.29× · Cheapest 25%
EV/EBITDA10.7× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)24· sector 36
PAST (return on equity)42· sector 24
HEALTH (low debt)97· sector 97
DIVIDEND (yield)53· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sino-Argi Leading Biosciences Fair Value". https://www.fairvalue-calculator.com/stock/603970
Frequently asked questions
Is Sino-Argi Leading Biosciences (603970) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥8.32 versus a price of ¥12.17, about −32% upside (overvalued).
What is the fair value of 603970?
Our model-based fair value for Sino-Argi Leading Biosciences is ¥8.32 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥12.17.
What is the quality score of 603970?
Sino-Argi Leading Biosciences has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino-Argi Leading Biosciences (603970)?
Our model-based price target is the fair value of ¥8.32 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ¥5.20, optimistic scenario ¥13.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino-Argi Leading Biosciences stock forecast for 2026?
Our models put fair value at ¥8.32, about −32% upside versus a price of ¥12.17 (overvalued). Cautious scenario ¥5.20, optimistic scenario ¥13.17. The calculation is refreshed regularly with new filings.
What is the revenue of Sino-Argi Leading Biosciences (603970)?
Sino-Argi Leading Biosciences reported trailing-twelve-month revenue of about 11.4B CNY (latest available figure, as of Sep 24, 2026).
Does Sino-Argi Leading Biosciences pay a dividend?
Sino-Argi Leading Biosciences currently shows a dividend yield of about 2.63% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Sino-Argi Leading Biosciences (603970)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino-Argi Leading Biosciences it is ¥8.32 per share (as of Sep 24, 2026), against a price of ¥12.17. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Sino-Argi Leading Biosciences stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 603970 trades above its calculated fair value: price ¥12.17, fair value ¥8.32, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603970?
No. The price is what the market pays today (¥12.17); the fair value is what the company's own numbers justify (¥8.32). For Sino-Argi Leading Biosciences the two are ¥3.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino-Argi Leading Biosciences worth?
The market values Sino-Argi Leading Biosciences at about 3.3B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥12.17; our models calculate a fair value of ¥8.32 per share.
What do the bullish and bearish scenarios say about 603970?
Our models span a range for Sino-Argi Leading Biosciences: cautious scenario ¥5.20, base ¥8.32, optimistic ¥13.17 per share (as of Sep 24, 2026, price ¥12.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603970?
Sino-Argi Leading Biosciences trades at a price-to-earnings ratio of 18.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥8.32 is built from several models across several years. Other multiples: P/B 2.1, P/S 0.3, EV/EBITDA 10.7.
How solid is the balance sheet of Sino-Argi Leading Biosciences (603970)?
Balance-sheet figures for Sino-Argi Leading Biosciences (as of Sep 24, 2026): return on equity 10.6%, debt of 0.06 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 603970 from its 52-week high?
Sino-Argi Leading Biosciences trades at ¥12.17, about 15% below its 52-week high of ¥14.27 and 26% above the low of ¥9.63 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥8.32 is for.
Which stocks are comparable to Sino-Argi Leading Biosciences?
From the same area (Basic Materials) we also value Corteva, Inc, Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino-Argi Leading Biosciences stock attractive at the current price?
The data as of Sep 24, 2026: price ¥12.17, calculated fair value ¥8.32 (−32%), Quality Score 57/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603970 calculated?
We run Sino-Argi Leading Biosciences through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥8.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Sino-Argi Leading Biosciences itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino-Argi Leading Biosciences (603970)?
The closing price on Sep 24, 2026 was ¥12.17. Our model-based fair value is ¥8.32, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino-Argi Leading Biosciences right now?
Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥5.20 to ¥13.17) leaves room in how you read the outcome.
Where does the earnings growth of Sino-Argi Leading Biosciences (603970) come from?
Earnings per share at Sino-Argi Leading Biosciences grew +7.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share +11.8 %, EBIT margin +1.6 %, tax rate +0.6 %, residual (interest, one-offs) −5.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sino-Argi Leading Biosciences
How large is the market capitalisation of Sino-Argi Leading Biosciences (603970)?
The market capitalisation of Sino-Argi Leading Biosciences is 3.3B CNY (≈ $488M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sino-Argi Leading Biosciences (603970)?
The price-to-sales ratio of Sino-Argi Leading Biosciences is 0.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sino-Argi Leading Biosciences (603970)?
Earnings per share at Sino-Argi Leading Biosciences are ¥0.6500 (price ÷ EPS = P/E 18.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sino-Argi Leading Biosciences (603970)?
The dividend yield of Sino-Argi Leading Biosciences is 2.6% (payout 49.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino-Argi Leading Biosciences (603970)?
The net margin of Sino-Argi Leading Biosciences is 1.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino-Argi Leading Biosciences (603970)?
The return on equity (ROE) of Sino-Argi Leading Biosciences is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino-Argi Leading Biosciences (603970)?
On an EBIT basis the return on assets of Sino-Argi Leading Biosciences is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino-Argi Leading Biosciences (603970)?
The operating margin of Sino-Argi Leading Biosciences is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino-Argi Leading Biosciences (603970)?
Revenue at Sino-Argi Leading Biosciences is growing +4.8% versus a year earlier (3y avg −1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino-Argi Leading Biosciences (603970)?
Earnings per share at Sino-Argi Leading Biosciences are growing +1.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sino-Argi Leading Biosciences (603970) generate?
The free cash flow of Sino-Argi Leading Biosciences is −79.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sino-Argi Leading Biosciences (603970) carry?
The net debt of Sino-Argi Leading Biosciences is 308M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sino-Argi Leading Biosciences in the live analysis
One click puts Sino-Argi Leading Biosciences on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
